| Name | Title | Contact Details |
|---|
MEDX Ventures Group, founded in 2010, is an investment and management company with offices in Israel, USA and Europe. The company believes in active management (as opposed to passive investment), and is focusing on medical ventures and technologies in Israel while utilizing the Company`s unique X Model to include its core Development, Regulatory, Commercial and Finance team that manages a portfolio of ventures. MEDX Ventures Group capitalizes on its global presence while utilizing Israel`s unique research, development and operations capabilities in the field; As such the company focuses on smart investment, reduced risk, short time to market and efficient return on investment. MEDX Ventures Group is led by highly experienced medical device management and investment team from different aspects of the business to ensure the Company`s X Model is fully implemented and executed in each of its activities and ventures. In addition, the company continuously seeks alliances with global industry leaders, beginning in project development stage, to ensure medical innovations become the life changing reality for patients and providers, while becoming a profitable business to all stakeholders and generating attractive return for investors.
Minimally Invasive Technology for Obstructive Sleep Apnea
Qvella is a molecular diagnostics company with the goal of dramatically reducing time to results in bacteriology. The company has developed a highly differentiated technology for pathogen detection by direct sampling of boldily fluids without the need for culturing or time consuming sample processing.
Health Link is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed`s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals in the clinical assessment of secondary lymphoedema of the arm in female breast cancer patients.